Pulmatrix Takes $14 Mil. From Insiders, Sharpens Focus On Dry-Powder Inhaler Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
With the Series B extension, the company will conduct Phase Ib and IIa studies in COPD and cystic fibrosis, while aiming to partner one indication.